Journal of Clinical Oncology
Articles in this Issue
Impact of FLT3 inhibitors on the outcomes of FLT3-ITD-positive acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysis.
e18503 Background: Acute Myeloid Leukemia (AML) with FLT3-ITD mutations has poor prognosis and high relapse rates after allogeneic hematopoietic stem cell...
Outcomes of stage II-IVA esophageal and esophagogastric cancers treated with multimodal therapy: A 13-year single-center study.
e16126 Background: The treatment landscape for locoregional esophageal (Eso) and gastroesophageal junction (GEJ) cancers (Ca) has evolved significantly ov...
Survival outcomes for patients with extensive stage small cell lung cancer (ES-SCLC) treated with consolidative thoracic radiation therapy (cTRT) and chemoimmunotherapy (CIT): A population level study.
e20126 Background: CIT has been adopted as the first-line treatment for ES-SCLC, supported by clinical trials which showed significant survival benefits....
Long-term survival after luveltamab tazevibulin, a novel folate receptor-α (FRα) targeting antibody drug conjugate (ADC) in children with CBFA2T3::GLIS2 acute myeloid leukemia (AML).
e22007 Background: CBFA2T3::GLIS2 (CBF/GLIS2) rearranged AML is a highly refractory AML subtype arising in infants and young child...
Gene expression signatures (GES) derived from digital histology to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (CT) in ISPY2 and other trial/real world cohorts.
587 Background: GES predictive of response to therapy across multiple breast cancer subtypes are commercially available or in development. Deep learning m...
Ibrutinib, venetoclax plus CD20 monoclonal Ab: Initial results of OASIS II, a prospective randomized phase 2 trial in previously untreated mantle cell lymphoma patients.
7044 Background: Ibrutinib is approved in R/R MCL. Enrich trial (Lewis, ASH 2024, abst 235) showed that Ibrutnib/CD20mAb outperforms chemotherapy front-li...
Chemotherapy and supportive care practice patterns among older adults with metastatic pancreatic cancer.
e16373 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a leading cause of cancer-related mortality in the U.S. Multi-agent chemotherapy...
Autoimmune conditions and ‘breast implant illness’ in breast cancer patients with implant-based breast reconstructions.
12035 Background: The safety of silicone breast implants (SBIs) has been challenged in various large observational studies that suggest an association wit...
Assessing the association between cycles of fertility treatments with gonadotropins and cancer risk.
10599 Background: Fertility treatments such as in vitro fertilization (IVF) and controlled ovarian hyperstimulation relies on exogenous hormones known as...
Safety and efficacy of endoscopic treatment with mucosal resection, radiofrequency ablation, and cryotherapy in the curative treatment of early esophageal squamous cell cancer and dysplasia.
4055 Background: Endoscopic esophageal treatment (EET), by radiofrequency ablation (RFA), cryoablation (Cryo), and endoscopic mucosal resection (EMR) has...
ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update.
3041 Background: Treatment options are limited for patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) that progress after platinum-based...
Cancer-related mortality of incarcerated populations in the United States.
11050 Background: The United States has the largest incarcerated population of any country in the world with 1.2 million prisoners as of 2022, but little...
Outpatient administration of CAR T-cell therapy: A University of Arizona Cancer Center experience.
e23167 Background: Chimeric antigen receptor T-cell (CAR T) therapy has traditionally been administered in an inpatient setting. This approach is associat...
Evaluating lung cancer screening using low dose computed tomography (LDCT) scan in a community hospital: A retrospective study.
e23060 Background: Lung cancer is the leading cause of cancer-related deaths worldwide. The National Lung Screening Trial (NLST) showed that screening for...
The bubble effect: Impact of ASCO digital promotion on <i>Journal of Clinical Oncology</i> ( <i>JCO</i> ) download metrics (2023).
9042 Background: The impact of digital promotion on scientific article metrics remains debated. This study examined how ASCO’s digital promotion via Twitt...
Mesothelioma showdown: Surgery vs. chemo—When the numbers don’t agree.
e20093 Background: Malignant mesothelioma is an aggressive malignancy with limited treatment options and poor survival outcomes. This study compares 4-yea...
Incidence of myelodysplastic syndrome in patients treated with PARP inhibitors: A systematic review.
e18583 Background: Polyadenosine diphosphate-ribose polymerase inhibitors (PARPi) have revolutionized the treatment landscape for various cancers. However...
Empowering young-onset colorectal cancer patients with an accessible, self-navigable online platform for universal germline testing.
11004 Background: Since 2022, the National Comprehensive Cancer Network (NCCN) has recommended universal germline testing (UGT) for all individuals diagno...
Patient characteristics and utilization patterns of olaparib in patients with early-stage breast cancer (eBC): Real-world insights using Komodo Healthcare Map (KHM).
e12502 Background: In March 2022, the United States Food and Drug Administration approved olaparib as adjuvant treatment (tx) for patients with germline B...
Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma.
7046 Background: Treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is challenging despite advances. AZD0486, a novel IgG4 fully hum...
Use of targeted therapy, healthcare costs, and survival with large panel testing, narrow testing, or no molecular testing in patients with metastatic non-small cell lung cancer (mNSCLC).
8642 Background: Treatment guidelines recommend broad molecular profiling for patients with mNSCLC. With the availability of molecular tests with differen...
Impact of performance status on outcomes for solid tumor patients receiving inpatient chemotherapy.
e23079 Background: Inpatient chemotherapy (IC) administration is often associated with high mortality, aggressive end of life care, and high healthcare co...
Peri-transplant supportive and palliative care and/or comorbidity management for older, medically infirm, and/or frail recipients of allogeneic hematopoietic cell transplantation (Allo-HCT): Phase II and interim phase III trial analyses.
12011 Background: Patients (pts) with high HCT-Comorbidity Index scores (HCT-CI of ≥3), older age (≥65 years), and/or who are frail per gait speed (<0....
Can ChatGPT perform as well as pharmacists in identifying potentially inappropriate medications (PIMs) in elderly cancer patients?
e23121 Background: Polypharmacy remains a significant issue among older adults, primarily due to its association with an increased risk of potentially ina...
Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial.
7501 Background: Minimal residual disease (MRD) negativity (neg) and sustained MRD neg are associated with longer survival...